N/A
Manufactured by Bausch & Lomb Incorporated
28,955 FDA adverse event reports analyzed
Last updated: 2026-04-14
POLYETHYLENE GLYCOL 400 is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Bausch & Lomb Incorporated. The most commonly reported adverse reactions for POLYETHYLENE GLYCOL 400 include DRUG INEFFECTIVE, INCORRECT PRODUCT ADMINISTRATION DURATION, OFF LABEL USE, NAUSEA, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for POLYETHYLENE GLYCOL 400.
Out of 11,919 classified reports for POLYETHYLENE GLYCOL 400:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 28,955 FDA FAERS reports that mention POLYETHYLENE GLYCOL 400. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, INCORRECT PRODUCT ADMINISTRATION DURATION, OFF LABEL USE, NAUSEA, DIARRHOEA, CONSTIPATION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Bausch & Lomb Incorporated in connection with POLYETHYLENE GLYCOL 400. Always verify the specific product and NDC with your pharmacist.